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A B S T R A C T
Over the recent years it has become abundantly clear that reperfusion by primary 
angioplasty in patients with ST-elevation myocardial infarction (STEMI) is the treat-
ment of choice. For hospitals that lack facilities for percutaneous coronary interven-
tion (PCI), on site thrombolysis remains their first option, or alternatively patients 
can be transferred to other institutions for PCI, if this can be accomplished within a 
tight time frame. For the latter strategy, an organized network of centers is needed to 
rapidly and safely transfer STEMI patients for primary PCI. Thus, although transfer-
ring STEMI patients for primary PCI appears to be a superior reperfusion strategy 
compared with on-site fibrinolysis at a no-PCI capable hospital, time delays associ-
ated with transferring patients for PCI in routine clinical practice remains a major 
drawback of the whole concept.
The tight time interval of 90-120 min needed to take full advantage of primary PCI, 
probably can be extended several hours, if an initial reperfusion treatment with throm-
bolysis is chosen, followed by routine angioplasty in the subsequent hours. This strat-
egy, also referred as adjunctive PCI after thrombolysis in the literature, is easily dif-
ferentiated from facilitated PCI, when a thrombolytic regimen is specifically used to 
maximize initial reperfusion rate and not in order to `gain` time, and ischemia-driven 
PCI, when an intervention becomes mandatory after objective evidence of post-inf-
arction ischemia. At least these are the convincing results from recent trials published 
over the last three years, such as TRANSFER-AMI, FAST-MI, GRACIA-2, WEST-
MI, CARESS-AMI and NORDISTEMI.
When used early after the onset of symptoms, a pharmacoinvasive strategy that com-
bines thrombolysis with a liberal use of PCI yields early and 1-year survival rates that 
are comparable to those of primary PCI. Finally, when analyzed according to the tim-
ing of PCI after thrombolysis, mortality tended to be lower with increasing time from 
thrombolysis when PCI was performed on a systematic basis, whereas it tended to 
increase with increasing time from thrombolysis when PCI was performed as a rescue 
procedure. Sufficient time course, probably >2-3 hours to 6-12 hours, which neutral-
izes the pre-hemorrhagic effect of thrombolysis and allows the antiplatelet agents to 
act, is the key point for a better outcome when thrombolysis is combined with early 
angioplasty. This appears to be a more effective and practical way to treat STEMI 
patients, at least for those hospitals, whereby immediate PCI is not available.
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i N T R o d U C T i o N
In the middle of this decade the publication by Keeley et 
al.1 of their comprehensive meta-analysis comparing intrave-
nous thrombolytic treatment and angioplasty in ST elevation 
myocardial infarction (STEMI) convinced the vast majority 
of cardiologists that reperfusion by angioplasty should be the 
treatment of choice. Nevertheless, the fact that many hospitals 
lack facilities for percutaneous coronary intervention (PCI), 
and thus objective problems exist as how to organize in an ap-
propriate time fashion the transport of such patients together 
with alternative therapies of combined pharmacoinvasive 
therapies, led to a relative delay in obtaining clear guidelines 
for the optimal treatment of STEMI. In the beginning of 2010, 
recent data determining the ideal time interval for intervention 
coupled with a variety of relative trial results (trial acronyms 
explained in Table 1), seem to clarify the chapter of STEMI 
treatment better. Consequently, some reminders regarding 
the practice of transfer STEMI patients for subsequent an-
gioplasty and the idea of pharmacoinvasive reperfusion before 
mechanical recanalization, in conjunction with the appropriate 
time interval to perform such strategies, are needed.
T R A N S f e R R i N g  S T e M i  PA T i e N T S  f o R 
P R i M A R y  P C i
The concept of transferring patients with STEMI for 
primary PCI was supported by a number of trials. In the 
largest experience of transfer for primary PCI, the Danish 
Multicenter Randomized Trial on Thrombolytic Therapy 
Versus Acute Coronary Angioplasty in Acute Myocardial 
Infarction (DANAMI-2), 1.572 patients with STEMI were 
randomly assigned to on-site accelerated tissue plasminogen 
activator or primary PCI at 24 hospitals in Denmark.2 Patients 
who were randomized to primary PCI at referral centers were 
transferred to one of 5 invasive centers, provided that the 
transfer would likely take up to 3 hours. The DANAMI-2 trial 
was stopped early because of an approximately 40% lower 
incidence of the primary end point of recurrent myocardial 
infarction, disabling stroke, or death at 30 days with primary 
PCI compared with fibrinolysis (8.5% vs. 14.2%; p=0.002). 
This initial experience has shown that an organized network 
of centers could rapidly and safely transfer STEMI patients 
for primary PCI.
In the PRAGUE study (PRimary Angioplasty in patients 
transferred from General community hospitals to specialized 
PTCA Units with or without Emergency thrombolysis), the 
safety and feasibility of interhospital transfer of patients with 
STEMI in the Czech Republic was evaluated.3 Patients were 
randomly assigned to three groups: group A received intra-
venous streptokinase; group B received streptokinase with 
immediate transfer to an invasive center for subsequent PCI; 
and group C was transported to an invasive center without 
receiving fibrinolytic therapy. Transfer was tolerated well, 
with rare nonfatal complications and no deaths. The primary 
composite end point (reinfarction, stroke, or death at 30 days) 
was reduced across groups A, B, and C (23%, 15%, and 8%, 
respectively; p <0.02). The following PRAGUE-2 trial4 ran-
domized 850 STEMI patients from community hospitals in 
the Czech Republic to on-site fibrinolysis with streptokinase 
or transfer to invasive centers for primary PCI. There was a 
modest trend toward reduction in the primary end point of 
30-day mortality with primary PCI versus streptokinase (6.8% 
vs. 10.0%; p <0.12). Analysis of a prespecified subgroup of 
patients who presented within 3 hours of symptom onset 
showed no mortality benefit with transfer for PCI (7.3% vs. 
7.4%), whereas patients who presented within 3 to 12 hours 
of symptom onset had a significant reduction in mortality 
(6.0% vs. 15.3%; p <0.02). Therefore, the PRAGUE-2 results 
confirm the feasibility of transferring STEMI patients for 
primary PCI, but also suggest that transfer for primary PCI 
may primarily benefit patients who do not present soon after 
TABLe 1. List of trials` acronyms used in the text
1. AIR-PAMI: Air-Primary Angioplasty in Myocardial Infarc-
tion.
2. ASSENT-4 PCI: Assessment of the Safety and Efficacy of a 
New Treatment Strategy with Percutaneous Coronary Inter-
vention.
3. CARESS-AMI: Combined Abciximab REteplase Stent Study 
in Acute Myocardial Infarction
4. DANAMI: Danish Multicenter Randomized Trial on Throm-
bolytic Therapy Versus Acute Coronary Angioplasty in Acute 
Myocardial Infarction.
5. FAST-AMI: French Registry on Acute ST-Elevation Myocar-
dial Infarction.
6. FINESSE: Assessment of the Safety and Efficacy of a New 
Treatment Strategy with Percutaneous Coronary Interven-
tion.
7. GRACIA: GRupo de Analisis de la Cardiopatia Isquemica 
Aguda.
8. LIMI: Limburg Interventional Myocardial Infarction.
9. NORDISTEMI: NORwegian study on DIstrict treatment of 
ST-Elevation Myocardial Infarction.
10. PRAGUE: PRimary Angioplasty in patients transferred from 
General community hospitals to specialized PTCA Units with 
or without Emergency thrombolysis.
11. TRANSFER-AMI: Trial of Routine Angioplasty and Stenting 
after Fibrinolysis to Enhance Reperfusion in Acute Myocar-
dial Infarction.
12. WEST: Which Early ST-elevation myocardial infarction Ther-
apy.
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symptom onset. In the AIR-PAMI trial,5 patients transferred 
for primary PCI had a non-significant lower risk of reinfarc-
tion, disabling stroke, or death at 30 days (8.4% vs. 13.6%; 
p=0.33).
Recently published meta-analyses6,7 of results from fi-
brinolysis versus primary PCI trials, included data from 5 
trials (DANAMI-2, PRAGUE-1 and -2, AIR-PAMI, and the 
Limburg Intervention/MI trial) that compared on-site fibri-
nolysis with immediate transfer for primary PCI. Combined 
data from these trials showed that transfer for primary PCI 
was associated with a significant decrease in the composite 
end point of nonfatal myocardial infarction, stoke, or death 
compared with fibrinolysis (Table 2). These cumulative results 
underscore the concept that transferring STEMI patients for 
primary PCI appears to be a superior reperfusion strategy 
compared with on-site fibrinolysis at a no-PCI capable hos-
pital, but time delays associated with transferring patients for 
PCI in routine clinical practice may be a major drawback of 
the whole concept.
fA C i L i T A T e d  P C i
Stone et al8 observed that independently of the TIMI 
flow after a direct PCI in STEMI, the most important fac-
tor consists of how this flow stands before the beginning of 
PCI, as patients arriving with a TIMI III flow have a better 
prognosis than those arriving with TIMI 0, I, II flow, even if 
all of them have a TIMI III flow after the procedure. This 
observation generated the term «facilitated PCI» some years 
ago in order to describe the practice of an almost immediate 
PCI in STEMI, just preceded by some help from a fibrinolytic 
drug. This combination approach to a pharmacoinvasive re-
canalization has the rationale to reap the benefits and avoid 
the disadvantages of each method. It is well known that time 
to recanalization which generally favours thrombolysis and 
adequacy of restoration of perfusion that generally favours 
PCI were found to be pivotal determinants of a favourable 
outcome with either approach.
Compared with standard thrombolysis, which achieves 
TIMI 3 flow rates of 50% at 60 min and 60% at 90 min, 
primary angioplasty takes longer to perform, reducing the 
early benefit, but achieves greater TIMI 3 flow rates by 90 
min. Because pharmacologic intervention can be initiated 
immediately, it is a promising initial step. Because PCI prof-
fers more complete recanalization, it may be a particularly 
TABLe 2. Occurence of composite primary endpoint in different studies of Transfer-PCI, facilitated-PCI and thrombolysis 
followed by routine angioplasty.
TRANSfeR PCi
STUdy PCi included in initial treatment PCi not included in initial treatment P favours
(DANAMI-2)2 8.5% 14.2% p=0.002 PCI
(PRAGUE-1)3 8% 23% p<0.02 PCI
(PRAGUE-2)4-All 6.8% 10.0% p < 0.12 PCI
(PRAGUE-2)4 <3h 7.3% 7.4% p=NS NS
(PRAGUE-2)4 >3h 6.0% 15.3% p < 0.02 PCI
AIR-PAMI 5 8.4% 13.6% p=0.33 PCI
fACiLiTATed PCi
STUdy Primary PCi facilitated PCi P favours
ASSENT-4 PCI9 13% 19% p=0.0045 Primary PCI
FINESSE10 10.7% 9.8% p=0.55 NS
THRoMBoLySiS foLLowed By RoUTiNe ANgioPLASTy
STUdy Routine PCi post thrombolysis Rescue/delayed PCi P favours
TRANSFER-AMI13 11.0% 17.2% p=0.004 Routine PCI
CARESS16 4.4% 10.7% p=0.004 Routine PCI
NORDISTEMI18 6.0% 16.0% p=0.01 Routine PCI
Routine PCi post thrombolysis Primary PCi P favours
FAST-MI registry14 4.3% 5.0% p=NS NS
GRACIA-217 10% 12% p=0.57 NS
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welcome subsequent step. Although results of previous studies 
of routine early PCI after fibrinolytic therapy also demonstrate 
no convincing clinical benefit of facilitated PCI over standard 
PCI, their negative conclusions were attributed to the non-
use of stents, low-profile guiding catheters, steerable wires, 
and smaller-sized sheaths, and before platelet glycoprotein 
IIb/IIIa inhibitors and thienopyridines became available. 
However, recent results from 2 major clinical trials were also 
disappointing.9,10 In the ASSENT-4 PCI trial9 (Assessment 
of the Safety and Efficacy of a New Treatment Strategy with 
Percutaneous Coronary Intervention), 1.619 patients with 
STEMI of less than 6-hour duration were randomised to 
standard PCI (n=838) or PCI preceded by administration of 
full-dose tenecteplase (n=829). All patients received aspirin 
and a bolus, without an infusion, of unfractionated heparin. 
The median time from bolus tenecteplase to first balloon in-
flation was 104 min. The study was terminated early, because 
the primary end-point (a combination of death, or congestive 
heart failure or cardiogenic shock) was noted in 19% (151 of 
810) of patients assigned facilitated PCI versus 13% (110 of 
819) of those randomised to primary PCI (relative risk 1.39, 
95% CI 1.11–1.74; p=0.0045).
In the FINESSE trial10 (Assessment of the Safety and 
Efficacy of a New Treatment Strategy with Percutaneous 
Coronary Intervention) a total of 2.453 patients with STEMI 
who presented 6 hours or less after the onset of symptoms to 
receive combination-facilitated PCI, abciximab facilitated 
PCI, or primary PCI. The mean thrombolysis bolus-to-balloon 
time was 90 min. The primary end point was the composite of 
death from all causes, ventricular fibrillation occurring more 
than 48 hours after randomization, cardiogenic shock, and 
congestive heart failure during the first 90 days after rand-
omization. The primary end point occurred in 9.8%, 10.5%, 
and 10.7% of the patients in the combination-facilitated PCI 
group, abciximab-facilitated PCI group and primary-PCI 
group, respectively (P = 0.55); 90-day mortality rates were 
5.2%, 5.5% and 4.5%, respectively (P = 0.49). Overall, there 
was a graded increase in the rates of bleeding, intracranial 
hemorrhage and transfusions in the PCI-facilitated groups. 
In all three treatment groups combined, the rate of death was 
associated with the extent of bleeding (18.2% with TIMI major 
bleeding, 6.1% with TIMI minor bleeding, and 2.6% with little 
or no bleeding; P<0.001). According to author’s conclusions, 
neither facilitation of PCI with reteplase plus abciximab, nor 
facilitation with abciximab alone significantly improved the 
clinical outcomes, as compared with abciximab given at the 
time of PCI, in patients with STEMI.
The final damnation of facilitated PCI was signed again by 
Keeley et al.11 By identifying 17 trials of patients with STEMI 
assigned to facilitated (n=2.237) or primary (n=2.267) PCI, 
they report that the facilitated approach resulted in a greater 
than two-fold increase in the number of patients with initial 
TIMI grade 3 flow, compared with the primary approach 
(832 patients [37%] vs 342 [15%], odds ratio 3·18, 95% CI 
2.22–4.55); however, final rates did not differ (1706 [89%] vs 
1803 [88%]; 1.19, 0.86–1.64). Significantly more patients as-
signed to the facilitated approach than those assigned to the 
primary approach died (106 [5%] vs 78 [3%]; 1.38, 1.01–1.87), 
had higher non-fatal reinfarction rates (74 [3%] vs 41 [2%]; 1.71, 
1.16–2.51), and had higher urgent target vessel revascularisa-
tion rates (66 [4%] vs 21 [1%]; 2.39, 1.23–4.66). The increased 
rates of adverse events seen with the facilitated approach were 
mainly seen in thrombolytic-therapy-based regimens. Facili-
tated intervention was associated with higher rates of major 
bleeding than primary intervention (159 [7%] vs 108 [5%]; 
1.51, 1.10–2.08). Hemorrhagic stroke and total stroke rates 
were higher in thrombolytic-therapy-containing facilitated 
regimens than in primary intervention (hemorrhagic stroke 
15 [0.7%] vs two [0.1%], p=0.0014; total stroke 24 [1.1%] vs six 
[0.3%], p=0.0008). Thus, nowadays, facilitated PCI offers no 
benefit over primary PCI in STEMI treatment and facilitated 
interventions with thrombolytic-based regimens should be 
avoided (Table 1).
T H R o M B o Ly S i S  f o L L o w e d  B y  R o U T i N e 
A N g i o P L A S T y
The time to treatment with primary PCI is an important 
determinant of the clinical outcome among STEMI patients. 
Observations by Pinto et al12 made upon time delays in STE-
MI-related PCI are well known and they established a mean 
delay of 114 minutes not to be exceeded, in order to obtain a 
better therapeutic result with primary PCI, rather than phar-
macologic reperfusion with thrombolysis. But this time inter-
val probably seems to become longer if an additional 1-2 hours 
delay is added and probably more (but not exceeding 24 hours 
in total), if an initial reperfusion treatment with thrombolysis 
is chosen, followed by routine angioplasty in the subsequent 
hours. At least these are the convincing results from recent 
trials, such as TRANSFER-AMI, FAST-MI, GRACIA-2, 
WEST-MI, CARESS-AMI, NORDSTEMI, all published 
over the last three years and summarized in Table 2.
In the TRANSFER-AMI trial13 (Trial of Routine Angi-
oplasty and Stenting after Fibrinolysis to Enhance Reperfusion 
in Acute Myocardial Infarction), 1.059 high-risk patients who 
had a STEMI and who were receiving fibrinolytic therapy at 
centers that did not have the capability of performing PCI, 
were randomized to either standard treatment (including 
rescue PCI, if required, or delayed angiography) or a strategy 
of immediate transfer to another hospital and PCI within 6 
hours after fibrinolysis. All patients received aspirin, tenect-
eplase, and heparin or enoxaparin; concomitant clopidogrel 
was recommended. The primary end point was the composite 
of death, reinfarction, recurrent ischemia, new or worsen-
ing congestive heart failure, or cardiogenic shock within 30 
days. PCI was performed in 67,4% of the patients assigned to 
standard treatment a median of 21.9 hours after randomiza-
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tion and in 84.9% of the patients assigned to routine early PCI 
a median of 3.9 hours after administration of tenecteplase. 
At 30 days, the primary end point occurred in 11.0% of the 
patients who were assigned to routine early PCI and in 17.2% 
of the patients assigned to standard treatment (relative risk 
with early PCI, 0.64; 95% confidence interval, 0.47 to 0.87; p 
= 0.004). There were no significant differences between the 
groups in the incidence of major bleeding.
Interestingly, the same findings described in the TRANS-
FER-AMI were available almost one year ago from the 
FAST-MI registry14 (French Registry on Acute ST-Eleva-
tion Myocardial Infarction), which rather than a trial, is a 
report of daily practice of STEMI treatment in France. The 
purpose of the study was to assess contemporary outcomes 
in STEMI patients, with specific emphasis on comparing a 
pharmacoinvasive strategy (thrombolysis followed by routine 
angiography) with primary PCI. Of the thrombolysis group 
96% underwent subsequent angiography, with 84% undergo-
ing PCI (58% within 24 hours of receiving thrombolysis). In 
the thrombolysis cohort the mean time interval from lysis to 
PCI was 290 minutes and in the primary PCI group 300 min. 
In-hospital mortality was 5.0% in patients with primary PCI 
and 4.3% in those with thrombolysis. One-year survival was 
94% for thrombolysis and 93% for primary PCI. Thus, when 
used early after the onset of symptoms, a pharmacoinvasive 
strategy that combines thrombolysis with a liberal use of PCI 
yields early and 1-year survival rates that are comparable to 
those of primary PCI. Finally, when analyzed according to 
the timing of PCI after thrombolysis (according to quartiles 
of time delay from thrombolysis to PCI), 30-day mortality 
was 4.1% in the first and second quartiles (time from lysis to 
PCI=220 minutes) versus 3.6% in the third and fourth quar-
tiles; mortality tended to be lower with increasing time from 
thrombolysis when PCI was performed on a systematic basis, 
whereas it tended to increase with increasing time from throm-
bolysis when PCI was performed as a rescue procedure.
The results of WEST and GRACIA-2 trials are also in 
the same wavelength, as the WEST (Which Early ST-el-
evation myocardial infarction Therapy) trial15 showed that 
thrombolytic therapy followed by systematic PCI within 24 
hours yielded results comparable to those of primary PCI. 
More recently in the GRACIA-2 trial16 (GRupo de Analisis 
de la Cardiopatia Isquemica Aguda) a total of 212 STEMI 
patients were randomized to full tenecteplase followed by 
stenting within 3–12 hours of randomization (early routine 
post-fibrinolysis angioplasty; 104 patients), or to undergo 
primary stenting with abciximab within 3 hours of rand-
omization (primary angioplasty; 108 patients). The primary 
endpoints were epicardial and myocardial reperfusion, and the 
extent of left ventricular myocardial damage, determined by 
means of the infarct size and 6-week left ventricular function. 
Early routine post-fibrinolysis angioplasty resulted in higher 
frequency (21 vs. 6%, P=0.003) of complete epicardial and 
myocardial reperfusion (TIMI 3 epicardial flow and TIMI3 
myocardial perfusion and resolution of the initial sum of 
ST-segment elevation >70%) following angioplasty. Both 
groups were similar regarding infarct size (area under the 
curve of CK-MB: 4613±3373 vs 4649±3632 mg/L/h, P=0.94); 
6-week left ventricular function (ejection fraction: 59.0±11.6 
vs.56.2±13.2%, P=0.11; end-systolic volume index: 27.2±12.8 
vs. 29.7±13.6, P=0.21); major bleeding (1.9 vs. 2.8%, P=0.99) 
and 6-month cumulative incidence of the primary endpoint 
(10% vs. 12%, P=0.57; relative risk: 0.80; 95% confidence 
interval: 0.37–1.74).
Very recently, the results of the Combined Abciximab 
REteplase Stent Study (CARESS) trial17 confirmed that a 
policy of systematic PCI after thrombolysis was superior to 
a policy of PCI restricted to cases needing rescue based on 
symptoms and lack of resolution of ST elevation. In this trial 
the primary outcome (a composite of death, reinfarction, or 
refractory ischemia at 30 days, occurred in 13 patients (4.4%) 
in the immediate PCI group compared with 32 (10.7%) in the 
standard care/rescue PCI group (hazard ratio 0·40; 95% CI 
0.21–0.76, log rank p=0.004) and the time interval between 
thrombolysis and PCI was 135 minutes. In the NORDSTEMI 
trial18 (NORwegian study on DIstrict treatment of ST-Eleva-
tion Myocardial Infarction), a total of 266 patients with acute 
STEMI with more than 90-min transfer delays to PCI were 
treated with tenecteplase, aspirin, enoxaparin, and clopidogrel 
and randomized to immediate transfer for PCI or to standard 
management in the local hospitals with early transfer, only 
if indicated for rescue or driven-ischemia PCI. The median 
time from fibrinolysis to PCI was 163 min (2.7 hours) in the 
early invasive group and the composite of death, reinfarction, 
or stroke at 12 months was significantly reduced in the early 
invasive compared with the conservative group (6% vs. 16%, 
hazard ratio: 0.36, 95% confidence interval: 0.16 to 0.81, p= 
0.01).
Putting the puzzle together of time window appropriate 
and necessary with pharmacologic reperfusion with throm-
bolysis, what we observe is that in facilitated PCI trials when 
by protocol an immediate angioplasty was performed, the 
mean time was 104 min in ASSENT-4 and 90 min in FINESSE 
after thrombolysis. On the other hand, in trials when “early” 
angioplasty was performed later on after initial thrombolysis, 
either by protocol (3-12 hours in GRACIA-2) or by logistic 
reasons (2.7 hours in NORDSTEMI, 3.9 hours in TRANS-
FER-AMI, 4.8 hours in FAST-MI), results were better, even 
if the same thrombolytic treatment as in the PCI facilitated 
trials was used. It is obvious the longer delay between fibri-
nolysis and PCI may also reduce the risk of bleeding resulting 
in an increased efficacy of a such a strategy. Fibrinolysis is 
associated with increased platelet activation and aggregation, 
which can be counteracted with potent antiplatelet therapy. 
The prothrombotic state that exists after administration of 
fibrinolysis, may be amplified when coronary stenting is per-
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formed within hours after fibrinolysis. Thus, a potent adjunc-
tive antithrombotic treatment is needed, although the adjunct 
antithrombotic therapy may impact on the risk of ischemic 
and hemorrhagic complications when PCI is performed (very) 
early after fibrinolysis. Finally, the specific time course (prob-
ably more than 2-3 hours up to 6-12 hours) which neutralizes 
the pre-hemorrhagic effect of thrombolysis and allows the 
antiplatelet effects of old and new potent drugs (clopidogrel, 
prasugrel) to act is the key point for a better outcome when 
thrombolysis is combined with early angioplasty.
In conclusion, almost three decades after initiation of 
intravenous thrombolysis and/or angioplasty as treatment of 
STEMI, the interaction of time appropriateness and avail-
ability to apply interventional techniques, in the context of an 
evolving atherothrombotic process, in conjunction with better 
knowledge of the pathophysiology of the fibrinolytic proper-
ties, elucidated and clarified the whole spectrum of therapeutic 
interventions. Terms as facilitated, rescue, delayed or elective 
PCI after myocardial infarction make no more sense and the 
glossary of current therapeutic choices became shorter and 
simpler, as the key word is actually reperfusion and as such 
it should be obtained, either by primary PCI or thrombolysis 
followed by routine angioplasty (adjunctive PCI) as the more 
effective ways to treat STEMI patients.
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